Enlight Renewable Energy Ltd.: The Company may double its revenues within two years; price target is NIS 2.30. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnlight Renewable Energy Ltd.: The Company may double its revenues within two years; price target is NIS 2.30.
Enlight Renewable Energy Ltd: Significant regualtory progress brings Enlight closer to final-stage approvals for the Bereshit wind farm; stock target price unchanged. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnlight Renewable Energy Ltd: Significant regualtory progress brings Enlight closer to final-stage approvals for the Bereshit wind farm; stock target price unchanged.
Enlight Renewable Energy Ltd: Revenues from sales of electricity in 2017 met expectations; full commercial operation in Ireland; a growing project pipeline; stock target price remains at 2.30. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnlight Renewable Energy Ltd: Revenues from sales of electricity in 2017 met expectations; full commercial operation in Ireland; a growing project pipeline; stock target price remains at 2.30.
Energix Renewable Energies Ltd.: Combining green energy growth opportunities with Fix Assets returns Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix Renewable Energies Ltd.: Combining green energy growth opportunities with Fix Assets returns
Energix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05.
Energix: Polish Power Exchange reforms have a positive effect; stake in Ilawa Wind Energy project in Poland increased from 75% to 100%; all projects in development are progressing according to schedule; target price raised to NIS 4.61 Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix: Polish Power Exchange reforms have a positive effect; stake in Ilawa Wind Energy project in Poland increased from 75% to 100%; all projects in development are progressing according to schedule; target price raised to NIS 4.61
Energix Renewable Energies Ltd.: Completion of stage II connection to the company’s flagship Polish project and successful capital raising are positive indicators. We have raised the price target to NIS 3.82. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix Renewable Energies Ltd.: Completion of stage II connection to the company’s flagship Polish project and successful capital raising are positive indicators. We have raised the price target to NIS 3.82.
Energix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged.
DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingDNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.
DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingDNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.
